drugset / Trial / NCT07691489
A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Phase 2
Not yet recruiting
27 enrolled
Memorial Sloan Kettering Cancer Center
AstraZeneca · collabEli Lilly and Company · collabNational Institutes of Health (NIH) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is find out whether the combination of trastuzumab deruxtecan (T-DXd) and cetuximab is an effective treatment for participants with metastatic and/or unresectable colorectal cancer that expresses low levels of HER2 and that has gotten worse after receiving standard treatment.
Timeline
- Start
- 2026-08
- Primary completion
- 2029-06
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | — | — |